Previous close | 6.28 |
Open | 6.26 |
Bid | 6.55 x 100 |
Ask | 6.81 x 100 |
Day's range | 6.26 - 6.76 |
52-week range | 2.70 - 9.97 |
Volume | |
Avg. volume | 169,378 |
Market cap | 285.617M |
Beta (5Y monthly) | 3.17 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.34 |
Earnings date | 08 May 2024 - 12 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 13.75 |
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs Conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by corre
Foghorn Therapeutics Inc. (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The consensus price target hints at a 124.3% upside potential for Foghorn Therapeutics Inc. (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.